The accompanying table (click to enlarge) includes the Top 10 Rated companies among a total of 64 and statistics for the ETF Innovators (ETFI) Cosmetic and Reconstructive Medicine (CRM) Index, which includes companies with market caps over $100M engaged in cosmetic medicine products, regenerative medicine + stem cells, orthopedic repair, joint replacements, and cardiovascular (heart + blood vessels) treatments.
The Top 10 Rated companies are dominated by those focusing on cardiovascular treatments, including VNUS Medical Technologies (VNUS), Thoratec (NASDAQ:THOR), Edwards Lifesciences (NYSE:EW), Vascular Solutions (NASDAQ:VASC), ATS Medical (ATSI), and Abiomed (NASDAQ:ABMD).
Over the past year, the Top 40 Rated companies in the CRM Index fared better than the Healthcare Sector SPDR (NYSEARCA:XLV), iShares Nasdaq Biotech ETF (NASDAQ:IBB), and the S&P 500 SPDR (NYSEARCA:SPY) – thanks in part to a major surge in six stem cell and regenerative medicine companies highlighted below with their one-month stock price return and current market cap:
Osiris Therapeutics (NASDAQ:OSIR) up 10.9% to $603M
Cytori Therapeutics (NASDAQ:CYTX) up 87.6% to $110M
RTI Biologics (NASDAQ:RTIX) up 48.5% to $157M
Integra LifeSciences (NASDAQ:IART) up 15.4% to $967M
StemCells (NASDAQ:STEM) up 20.6% to $122M
Geron (NASDAQ:GERN) up 45% to $367M
The new administration is viewed as favorable for increased spending on basic scientific research (including stem cells) and, more importantly, companies such as Pfizer (NYSE:PFE), Roche (OTCQX:RHHBY), Johnson & Johnson (NYSE:JNJ), Novartis (NYSE:NVS), and GlaxoSmithKline (NYSE:GSK) are starting business segments focused on regenerative medicine through direct investments and partnerships as a new frontier for R&D to bolster their pipelines.